©The Author(s) 2021.
World J Hepatol. Jul 27, 2021; 13(7): 804-814
Published online Jul 27, 2021. doi: 10.4254/wjh.v13.i7.804
Published online Jul 27, 2021. doi: 10.4254/wjh.v13.i7.804
Table 1 Types, specific agents, and acting duration of commonly used antithrombotic drugs
| Class of agents | Type | Specific agents | Duration of action |
| Antiplatelets | |||
| Thienopyridines | Clopidogrel (Plavix), ticlopidine (Panardine), prasugrel (Effient), ticagrelor (Brilinta) | 5-7 d1 | |
| Type III PDE inhibitor | Cilostazol (Pretal) | 2 d | |
| Acetylsalicylic acid | Aspirin | 7-10 d | |
| Other NSAIDs | Ibuprofen (Brufen, Advil), loxoprofen (Loxonin), diclofenac (Voltaren) etc. | Varies | |
| Anticoagulants | |||
| Heparin (unfractionated) | Heparin | 1-2 h | |
| Heparin (LMWH) | Dalteparin (Fragmin iv), enoxaparin (Clexane, s.c.), nadroparin (s.c.) | 6-12 h2 | |
| Vitamin K antagonist | Warfarin (Coumadin) | 5 d | |
| Factor Xa inhibitor (s.c.) | Fondaparinux (Arixtra) | 1-1.5 d | |
| DOACs | |||
| Direct thrombin inhibitor | Dabigatran (Pradaxa) | 1-2 d | |
| Factor Xa inhibitors | Rivaroxaban (Xarelto), apixaban (Eliquis), edoxaban (Lixiana) | 1-2 d |
- Citation: Fujikawa T. Safety of liver resection in patients receiving antithrombotic therapy: A systematic review of the literature. World J Hepatol 2021; 13(7): 804-814
- URL: https://www.wjgnet.com/1948-5182/full/v13/i7/804.htm
- DOI: https://dx.doi.org/10.4254/wjh.v13.i7.804